Jacques Näsström has been appointed CEO and Michaela Johansson CFO of the company. PledPharma will be evaluating various options for the funding of further studies following the positive Phase II results presented today.
Jacques Näsström comes from Q-Med, where he has been Head of Research since 2006. Jacques has a background in pharmacology and 25 years of experience in the pharmaceutical and biotechnology industries, including a position as Investment Manager at Karolinska Investment Fund, and various positions within drug development at Astra and AstraZeneca.
Michaela Johansson comes from the parent company, Accelerator Nordic, where she was responsible for stock market information and worked with analyses and capital acquisition. Michaela previously worked as an analyst at ITP Invest.
“I look forward to being in charge of the development of PledPharma, it is a very exciting company. In addition to the first indications for colorectal cancer, we see great potential for PP-095 in other chemotherapy and types of cancer.” says PledPharma’s CEO Jacques Näsström.
PledPharma will be evaluating options for the funding of further studies and one option, supported by the principal owners of Accelerator, is that the company is separated from the parent company and independently listed.
“It is time for PledPharma to take the step towards becoming an independent company. Accelerator will continue to be a major shareholder in the company, but we believe that time is now ripe to consider taking in new shareholders into the company, “says Accelerator’s CEO Andreas Bunge.
For further information, please contact Jan Olof Karlsson at +46 733 304 62
PledPharma AB develops new pharmaceutical applications based on a clinically approved PLEDderivative with an initial candidate for oncology. PledPharma’s core technology is an omnipotent low molecular weight enzyme mimetic (lowMEM) with SOD mimetic activity that has characteristics to protect healthy cells during cancer treatment with chemotherapy and/or radiation. When used as an adjunct treatment, it has the potential to improve both clinical outcomes and patient well-being. In addition to cancer treatment, SOD mimetics have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases.
For more information, please visit www.pledpharma.se